GELSOMINO, FRANCESCO
GELSOMINO, FRANCESCO
DIPARTIMENTO DI MEDICINA SPECIALISTICA, DIAGNOSTICA E SPERIMENTALE (attivo dal 28/10/2011 al 31/12/2022)
Collaboratori
Peripheral nervous system adverse events associated with immune checkpoint inhibitors
2023 Rossi S.; Gelsomino F.; Rinaldi R.; Muccioli L.; Comito F.; Di Federico A.; De Giglio A.; Lamberti G.; Andrini E.; Mollica V.; D'Angelo R.; Baccari F.; Zenesini C.; Madia P.; Raschi E.; Cortelli P.; Ardizzoni A.; Guarino M.
Phase II study of capecitabine-based concomitant chemoradiation followed by durvalumab as a neoadjuvant strategy in locally advanced rectal cancer: the PANDORA trial
2023 Grassi, E; Zingaretti, C; Petracci, E; Corbelli, J; Papiani, G; Banchelli, I; Valli, I; Frassineti, G L; Passardi, A; Di Bartolomeo, M; Pietrantonio, F; Gelsomino, F; Carandina, I; Banzi, M; Martella, L; Bonetti, A V; Boccaccino, A; Molinari, C; Marisi, G; Ugolini, G; Nanni, O; Tamberi, S
Immune checkpoint inhibitors in lung tumors with rare histologies and other thoracic malignancies
2022 Andrini E.; Di Federico A.; Sisi M.; Rosellini M.; Palladini A.; Lamberti G.; De Giglio A.; Gelsomino F.
Next-generation technologies in predictive molecular pathology of lung cancers
2022 de Biase, Dario; Maloberti, Thais; De Leo, Antonio; Sanza, Viviana; Visani, Michela; Gruppioni, Elisa; Altimari, Annalisa; Grillini, Alessia; Gelsomino, Francesco; Ferrari, Marco; Ardizzoni, Andrea; Tallini, Giovanni
Psychiatric Adverse Reactions to Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer: Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System
2022 Sisi, Monia; Fusaroli, Michele; De Giglio, Andrea; Facchinetti, Francesco; Ardizzoni, Andrea; Raschi, Emanuel; Gelsomino, Francesco
IFN-γ and CD38 in Hyperprogressive Cancer Development
2021 Angelicola, Stefania; Ruzzi, Francesca; Landuzzi, Lorena; Scalambra, Laura; Gelsomino, Francesco; Ardizzoni, Andrea; Nanni, Patrizia; Lollini, Pier-Luigi; Palladini, Arianna
Anti-programmed cell death-1 and anti-programmed cell death ligand-1 immune-related liver diseases: from clinical pivotal studies to real-life experience
2020 Vitale G.; Lamberti G.; Comito F.; Di Nunno V.; Massari F.; Morelli M.C.; Ardizzoni A.; Gelsomino F.
Atezolizumab in a CoHort of pretreated, advanced, non-small cell lung cancer patients with rare HistologiCal SubtypEs (CHANCE trial)
2020 Gelsomino F.; Lamberti G.; Tiseo M.; Rocco D.; Pasello G.; Cecere F.L.; Chella A.; Grilli G.; Mandruzzato M.; Tognetto M.; Garassino M.C.; Macerelli M.; Novello S.; Roila F.; Colantonio I.; Grossi F.; Fiorentino M.; Ardizzoni A.
Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma
2020 Lamberti G.; Andrini E.; Sisi M.; Rizzo A.; Parisi C.; Di Federico A.; Gelsomino F.; Ardizzoni A.
Evolution of cystic airspaces lung lesions on immune checkpoint inhibition in non-small cell lung cancer
2020 Parisi C.; Lamberti G.; Zompatori M.; Gelsomino F.; Salvagni S.; Sperandi F.; Ardizzoni A.
Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance
2020 Raschi E.; Gatti M.; Gelsomino F.; Ardizzoni A.; Poluzzi E.; De Ponti F.
New disappearance of complicated atheromatous plaques on rechallenge with PD-1/PD-L1 axis blockade in non-small cell lung cancer patient: follow up of an unexpected event
2020 Lamberti G.; Gelsomino F.; Brocchi S.; Poerio A.; Melotti B.; Sperandi F.; Gargiulo M.; Borghi C.; Fiorentino M.; Ardizzoni A.
Overcoming Primary Resistance to PD-1 Inhibitor With Anti–PD-L1 Agent in Squamous-Cell NSCLC: Case Report
2020 Gelsomino F.; Di Federico A.; Filippini D.M.; Dall'Olio F.G.; Lamberti G.; Sperandi F.; Balacchi C.; Brocchi S.; Ardizzoni A.
Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL)
2020 Gelsomino F.; Tiseo M.; Barbieri F.; Riccardi F.; Cavanna L.; Frassoldati A.; Delmonte A.; Longo L.; Dazzi C.; Cinieri S.; Colantonio I.; Sperandi F.; Lamberti G.; Brocchi S.; Tofani L.; Boni L.; Ardizzoni A.
Reliability of programmed death ligand 1 (PD-L1) tumor proportion score (TPS) on cytological smears in advanced non-small cell lung cancer: a prospective validation study
2020 Ricci C.; Capizzi E.; Giunchi F.; Casolari L.; Gelsomino F.; Rihawi K.; Natali F.; Livi V.; Trisolini R.; Fiorentino M.; Ardizzoni A.
The mechanisms of PD-L1 regulation in non-small-cell lung cancer (NSCLC): Which are the involved players?
2020 Lamberti G.; Sisi M.; Andrini E.; Palladini A.; Giunchi F.; Lollini P.-L.; Ardizzoni A.; Gelsomino F.
Complete Recalcification Following Arterial Embolization of Massive Osteolytic Bone Metastasis From NSCLC
2019 Francesco Gelsomino,Giancarlo Facchini, Maria Aurelia Barbera, Giuseppe Lamberti, Stefano Brocchi, Giuseppe Rossi, Andrea Ardizzoni
KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC
2019 Cinausero M.; Laprovitera N.; Maglio G.D.; Gerratana L.; Riefolo M.; Macerelli M.; Fiorentino M.; Porcellini E.; Buoro V.; Gelsomino F.; Squadrilli A.; Fasola G.; Negrini M.; Tiseo M.; Ferracin M.; Ardizzoni A.
The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC
2019 Mazzaschi, Giulia; Facchinetti, Francesco; Missale, Gabriele; Canetti, Diana; Madeddu, Denise; Zecca, Alessandra; Veneziani, Michele; Gelsomino, Francesco; Goldoni, Matteo; Buti, Sebastiano; Bordi, Paola; Aversa, Franco; Ardizzoni, Andrea; Quaini, Federico; Tiseo, Marcello
The evolving landscape of immunotherapy in small-cell lung cancer: A focus on predictive biomarkers
2019 Gelsomino, Francesco; Lamberti, Giuseppe; Parisi, Claudia; Casolari, Laura; Melotti, Barbara; Sperandi, Francesca; Ardizzoni, Andrea
| Titolo | Autore(i) | Anno | Periodico | Editore | Tipo | File |
|---|---|---|---|---|---|---|
| Peripheral nervous system adverse events associated with immune checkpoint inhibitors | Rossi S.; Gelsomino F.; Rinaldi R.; Muccioli L.; Comito F.; Di Federico A.; De Giglio A.; Lambert...i G.; Andrini E.; Mollica V.; D'Angelo R.; Baccari F.; Zenesini C.; Madia P.; Raschi E.; Cortelli P.; Ardizzoni A.; Guarino M. | 2023-01-01 | JOURNAL OF NEUROLOGY | - | 1.01 Articolo in rivista | Rossi_JN_2023.pdf |
| Phase II study of capecitabine-based concomitant chemoradiation followed by durvalumab as a neoadjuvant strategy in locally advanced rectal cancer: the PANDORA trial | Grassi, E; Zingaretti, C; Petracci, E; Corbelli, J; Papiani, G; Banchelli, I; Valli, I; Frassinet...i, G L; Passardi, A; Di Bartolomeo, M; Pietrantonio, F; Gelsomino, F; Carandina, I; Banzi, M; Martella, L; Bonetti, A V; Boccaccino, A; Molinari, C; Marisi, G; Ugolini, G; Nanni, O; Tamberi, S | 2023-01-01 | ESMO OPEN | - | 1.01 Articolo in rivista | main.pdf |
| Immune checkpoint inhibitors in lung tumors with rare histologies and other thoracic malignancies | Andrini E.; Di Federico A.; Sisi M.; Rosellini M.; Palladini A.; Lamberti G.; De Giglio A.; Gelso...mino F. | 2022-01-01 | IMMUNOTHERAPY | - | 1.01 Articolo in rivista | - |
| Next-generation technologies in predictive molecular pathology of lung cancers | de Biase, Dario; Maloberti, Thais; De Leo, Antonio; Sanza, Viviana; Visani, Michela; Gruppioni, E...lisa; Altimari, Annalisa; Grillini, Alessia; Gelsomino, Francesco; Ferrari, Marco; Ardizzoni, Andrea; Tallini, Giovanni | 2022-01-01 | Journal of Xiangya Medicine | - | 1.01 Articolo in rivista | 8323-PB5-2020-R3.pdf |
| Psychiatric Adverse Reactions to Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer: Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System | Sisi, Monia; Fusaroli, Michele; De Giglio, Andrea; Facchinetti, Francesco; Ardizzoni, Andrea; Ras...chi, Emanuel; Gelsomino, Francesco | 2022-01-01 | TARGETED ONCOLOGY | - | 1.01 Articolo in rivista | Sisi2022_Article_PsychiatricAdverseReactionsToA.pdf; 11523_2021_865_MOESM1_ESM.pdf |
| IFN-γ and CD38 in Hyperprogressive Cancer Development | Angelicola, Stefania; Ruzzi, Francesca; Landuzzi, Lorena; Scalambra, Laura; Gelsomino, Francesco;... Ardizzoni, Andrea; Nanni, Patrizia; Lollini, Pier-Luigi; Palladini, Arianna | 2021-01-01 | CANCERS | - | 1.01 Articolo in rivista | CD38 cancers-13-00309-v2.pdf |
| Anti-programmed cell death-1 and anti-programmed cell death ligand-1 immune-related liver diseases: from clinical pivotal studies to real-life experience | Vitale G.; Lamberti G.; Comito F.; Di Nunno V.; Massari F.; Morelli M.C.; Ardizzoni A.; Gelsomino F. | 2020-01-01 | EXPERT OPINION ON BIOLOGICAL THERAPY | - | 1.01 Articolo in rivista | - |
| Atezolizumab in a CoHort of pretreated, advanced, non-small cell lung cancer patients with rare HistologiCal SubtypEs (CHANCE trial) | Gelsomino F.; Lamberti G.; Tiseo M.; Rocco D.; Pasello G.; Cecere F.L.; Chella A.; Grilli G.; Man...druzzato M.; Tognetto M.; Garassino M.C.; Macerelli M.; Novello S.; Roila F.; Colantonio I.; Grossi F.; Fiorentino M.; Ardizzoni A. | 2020-01-01 | THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY | - | 1.01 Articolo in rivista | Gelsomino_CHANCE_TAMO'20.pdf |
| Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma | Lamberti G.; Andrini E.; Sisi M.; Rizzo A.; Parisi C.; Di Federico A.; Gelsomino F.; Ardizzoni A. | 2020-01-01 | CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | - | 1.01 Articolo in rivista | - |
| Evolution of cystic airspaces lung lesions on immune checkpoint inhibition in non-small cell lung cancer | Parisi C.; Lamberti G.; Zompatori M.; Gelsomino F.; Salvagni S.; Sperandi F.; Ardizzoni A. | 2020-01-01 | JOURNAL FOR IMMUNOTHERAPY OF CANCER | - | 1.01 Articolo in rivista | Parisi_Cystic airspaces_JIC'20.pdf |
| Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance | Raschi E.; Gatti M.; Gelsomino F.; Ardizzoni A.; Poluzzi E.; De Ponti F. | 2020-01-01 | TARGETED ONCOLOGY | - | 1.01 Articolo in rivista | ICI_Targeted_Oncology_2020.pdf; 11523_2020_738_MOESM1_ESM.pdf |
| New disappearance of complicated atheromatous plaques on rechallenge with PD-1/PD-L1 axis blockade in non-small cell lung cancer patient: follow up of an unexpected event | Lamberti G.; Gelsomino F.; Brocchi S.; Poerio A.; Melotti B.; Sperandi F.; Gargiulo M.; Borghi C....; Fiorentino M.; Ardizzoni A. | 2020-01-01 | THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY | - | 1.01 Articolo in rivista | Lamberti_atheromatous plaque_TAMO'20.pdf |
| Overcoming Primary Resistance to PD-1 Inhibitor With Anti–PD-L1 Agent in Squamous-Cell NSCLC: Case Report | Gelsomino F.; Di Federico A.; Filippini D.M.; Dall'Olio F.G.; Lamberti G.; Sperandi F.; Balacchi ...C.; Brocchi S.; Ardizzoni A. | 2020-01-01 | CLINICAL LUNG CANCER | - | 1.01 Articolo in rivista | - |
| Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL) | Gelsomino F.; Tiseo M.; Barbieri F.; Riccardi F.; Cavanna L.; Frassoldati A.; Delmonte A.; Longo ...L.; Dazzi C.; Cinieri S.; Colantonio I.; Sperandi F.; Lamberti G.; Brocchi S.; Tofani L.; Boni L.; Ardizzoni A. | 2020-01-01 | BRITISH JOURNAL OF CANCER | - | 1.01 Articolo in rivista | s41416-020-0845-3.pdf; 41416_2020_845_MOESM1_ESM.doc |
| Reliability of programmed death ligand 1 (PD-L1) tumor proportion score (TPS) on cytological smears in advanced non-small cell lung cancer: a prospective validation study | Ricci C.; Capizzi E.; Giunchi F.; Casolari L.; Gelsomino F.; Rihawi K.; Natali F.; Livi V.; Triso...lini R.; Fiorentino M.; Ardizzoni A. | 2020-01-01 | THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY | - | 1.01 Articolo in rivista | 1758835920954802.pdf |
| The mechanisms of PD-L1 regulation in non-small-cell lung cancer (NSCLC): Which are the involved players? | Lamberti G.; Sisi M.; Andrini E.; Palladini A.; Giunchi F.; Lollini P.-L.; Ardizzoni A.; Gelsomin...o F. | 2020-01-01 | CANCERS | - | 1.01 Articolo in rivista | Lamberti_PDL1_cancers-12-03129.pdf |
| Complete Recalcification Following Arterial Embolization of Massive Osteolytic Bone Metastasis From NSCLC |
Francesco Gelsomino,Giancarlo Facchini, Maria Aurelia Barbera, Giuseppe Lamberti, Stefano Bro...cchi, Giuseppe Rossi, Andrea Ardizzoni |
2019-01-01 | JOURNAL OF THORACIC ONCOLOGY | - | 1.01 Articolo in rivista | - |
| KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC | Cinausero M.; Laprovitera N.; Maglio G.D.; Gerratana L.; Riefolo M.; Macerelli M.; Fiorentino M.;... Porcellini E.; Buoro V.; Gelsomino F.; Squadrilli A.; Fasola G.; Negrini M.; Tiseo M.; Ferracin M.; Ardizzoni A. | 2019-01-01 | THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY | - | 1.01 Articolo in rivista | 2019_Immunotherapy.pdf |
| The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC | Mazzaschi, Giulia; Facchinetti, Francesco; Missale, Gabriele; Canetti, Diana; Madeddu, Denise; Ze...cca, Alessandra; Veneziani, Michele; Gelsomino, Francesco; Goldoni, Matteo; Buti, Sebastiano; Bordi, Paola; Aversa, Franco; Ardizzoni, Andrea; Quaini, Federico; Tiseo, Marcello | 2019-01-01 | LUNG CANCER | - | 1.01 Articolo in rivista | - |
| The evolving landscape of immunotherapy in small-cell lung cancer: A focus on predictive biomarkers | Gelsomino, Francesco; Lamberti, Giuseppe; Parisi, Claudia; Casolari, Laura; Melotti, Barbara; Spe...randi, Francesca; Ardizzoni, Andrea | 2019-01-01 | CANCER TREATMENT REVIEWS | - | 1.01 Articolo in rivista | - |